| Bioactivity | GSK1324726A is a novel, potent, and selective inhibitor of BET proteins with high affinity to BRD2 (IC50=41 nM), BRD3 (IC50=31 nM), and BRD4 (IC50=22 nM). | ||||||||||||
| Invitro | A panel of neuroblastoma cell lines are treated with GSK1324726A (I-BET726), and observed potent growth inhibition and cytotoxicity in most cell lines irrespective of MYCN copy number or expression level. All neuroblastoma cell lines tested exhibit potent growth inhibition, with a median growth IC50 value (gIC50; inhibitor concentration resulting in 50% growth inhibition) equal to 75 nM[1]. | ||||||||||||
| Name | GSK1324726A | ||||||||||||
| CAS | 1300031-52-0 | ||||||||||||
| Formula | C25H23ClN2O3 | ||||||||||||
| Molar Mass | 434.91 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
GSK1324726A
CAS: 1300031-52-0 F: C25H23ClN2O3 W: 434.91
GSK1324726A is a novel, potent, and selective inhibitor of BET proteins with high affinity to BRD2 (IC50=41 nM), BRD3 (I
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.